Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases

Allergy Asthma Proc. 2000 Mar-Apr;21(2):101-5. doi: 10.2500/108854100778250914.

Abstract

Stevens-Johnson syndrome (SJS) is a severe cutaneous eruption that can be a life-threatening emergency. Previously, we have reported our favorable experience in treating 54 patients with SJS with systemic corticosteroids. We continued our prospective analysis of consecutive patients with SJS treated with corticosteroids. Possible etiologic factors and clinical outcomes of the patients are described. All 13 patients improved with initiation of systemic corticosteroid therapy. There was no mortality or permanent sequelae attributable to SJS. Drugs were the offending agents in all 13 cases. There was one death unrelated to SJS. In conclusion, prompt treatment with systemic corticosteroids reduces morbidity and improves outcome of SJS patients. This analysis extends our series to 67 consecutive patients with SJS who were treated with corticosteroids and had a favorable outcome.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Dose-Response Relationship, Drug
  • Female
  • Follow-Up Studies
  • Glucocorticoids / administration & dosage*
  • Humans
  • Male
  • Methylprednisolone / administration & dosage*
  • Middle Aged
  • Prednisone / administration & dosage*
  • Prospective Studies
  • Severity of Illness Index
  • Stevens-Johnson Syndrome / diagnosis
  • Stevens-Johnson Syndrome / drug therapy*
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Prednisone
  • Methylprednisolone